Pharmacotherapy in obesity: the current state and the near future
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Yoon Jeong | - |
dc.contributor.author | Kim, Kyoung-Kon | - |
dc.date.accessioned | 2022-10-06T01:40:11Z | - |
dc.date.available | 2022-10-06T01:40:11Z | - |
dc.date.created | 2022-10-06 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/85618 | - |
dc.description.abstract | Background: In Korea, the prevalence of obesity, morbid obesity with serious complications, and childhood obesity are rapidly increasing. To control the obesity pandemic, both prevention and treatment are essential strategic targets. While lifestyle modification is fundamental in obesity treatment, due to the complex appetite-controlling system in the body and the rapidly Westernizing environment, more effective treatment tools are required. Current Concepts: There are 4 types of drugs that have been approved for the treatment of obesity in Korea. They are (1) appetite suppressants for short-term therapy, (2) dietary fat absorption inhibitors, (3) glucagon-like peptide-1 (GLP-1) receptor agonists, and (4) fixed-dose combination drugs for appetite control. However, a large amount of weight reduction cannot be achieved with these drugs. The greatest amount of weight reduction of approximately 11% has been reported for phentermine/topiramate combination treatment. Recently, peptide agents have been under development and 2 of these agents, semaglutide, a second generation GLP-1 receptor agonist, and tirzepatide, a glucose-dependent insulinotropic polypeptide/GLP-1 receptor dual agonist, are expected to be available in the near future. Discussion and Conclusion: Both semaglutide and tirzepatide are more effective than currently available anti-obesity drugs. Semaglutide and tirzepatide reduced the body weight of people with obesity without diabetes by 14.9% and 20.9%, respectively. However, because of the mechanism of GLP-1 receptor agonism, gastrointestinal adverse events, including nausea, diarrhea, vomiting, and abdominal pain, were problematic in many patients, although these adverse events were generally acceptable. Both drugs will be excellent options for obesity treatment in the near future. © Korean Medical Association. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | Korean Medical Association | - |
dc.relation.isPartOf | Journal of the Korean Medical Association | - |
dc.title | Pharmacotherapy in obesity: the current state and the near future | - |
dc.title.alternative | 비만 약물요법: 현재와 가까운 미래 | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000888818900007 | - |
dc.identifier.doi | 10.5124/jkma.2022.65.8.514 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Medical Association, v.65, no.8, pp.514 - 531 | - |
dc.identifier.kciid | ART002866554 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85138658286 | - |
dc.citation.endPage | 531 | - |
dc.citation.startPage | 514 | - |
dc.citation.title | Journal of the Korean Medical Association | - |
dc.citation.volume | 65 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Kim, Kyoung-Kon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Gastric inhibitory polypeptide | - |
dc.subject.keywordAuthor | Glucagon-like peptide-1 receptor | - |
dc.subject.keywordAuthor | Obesity | - |
dc.subject.keywordAuthor | Pharmacotherapy | - |
dc.subject.keywordPlus | CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | WEIGHT-LOSS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | CARDIOVASCULAR OUTCOMES | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | DOUBLE-DUMMY | - |
dc.subject.keywordPlus | BODY-WEIGHT | - |
dc.subject.keywordPlus | OVERWEIGHT | - |
dc.subject.keywordPlus | ADULTS | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.